Cyclacel Group plc (“Cyclacel”), the cell cycle-based biopharmaceutical company, announced today that it has commenced patient enrollment in a third Phase I trial of CYC682, a novel anticancer drug acting on the cell cycle. CYC682, an orally available small molecule nucleoside analog drug, is Cyclacel’s second candidate to enter clinical trials.
